Dalotuzumab (Not yet branded)
Immunotherapy
Description
Dalotuzumab (MK-0646) is a humanized monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R) pathway. This targeted therapy has been evaluated in metastatic colorectal cancer, particularly in combination with established treatments like cetuximab and irinotecan. The drug was developed to block IGF-1R signaling, which promotes tumor cell growth and survival in various cancer types including colorectal cancer.
Mechanism of Action
Dalotuzumab binds specifically to the insulin-like growth factor-1 receptor (IGF-1R), blocking the binding of IGF-1 and IGF-2 ligands to this receptor. This inhibition disrupts downstream signaling pathways including PI3K/AKT and MAPK pathways, which are critical for cancer cell proliferation, survival, and metastasis.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Immunotherapy |
 Status | Experimental |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Administration | IV |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.